AKBA — Akebia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517022 ·
Last close
$0.90
Market Cap
$249.56M
52W High
$1.46
52W Low
$0.81
ADV30
4,539,476
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 49,128,000 | 38,704,000 | -4,381,000 | -8,908,000 | 349,658,000 | 155,548,000 | 324,640,000 |
| Mar 2026 | 53,544,000 | 41,254,000 | -4,696,000 | -9,054,000 | 362,520,000 | 162,644,000 | 335,145,000 |
| Dec 2025 | 57,622,000 | 45,087,000 | -8,553,000 | -12,244,000 | 376,565,000 | 184,844,000 | 343,955,000 |
| Sep 2025 | 58,766,000 | 49,383,000 | 4,449,000 | 540,000 | 364,152,000 | 166,444,000 | 322,560,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,552,000
Investing CF
$-12,095,000
Financing CF
$-11,199,000
CapEx
$-12,095,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,701,667,000
Inventory
$13,018,000
Receivables
$53,506,000
ST Investments
—
EBIT TTM
$-10,509,000
Pretax Income TTM
$-27,846,000
Interest Exp TTM
$17,337,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$219,060,000
EBITDA
$-4,324,000
Free Cash Flow
$33,618,876
Enterprise Value
$294,864,512
Total Cash
$155,548,000
Total Debt
$199,188,000
Shares Out
277,106,245
Trailing EPS
$-0.12
Book Value
$0.09
ROE
-109.4%
ROA
-1.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 236,196,000 | 23,499,000 | -5,345,000 | 376,565,000 | 343,955,000 | — | 67,992,000 |
| Dec 2024 | 160,180,000 | -50,414,000 | -69,410,000 | 220,670,000 | 269,855,000 | — | -40,659,000 |
| Dec 2023 | 194,623,000 | -46,075,000 | -51,925,000 | 241,703,000 | 272,287,000 | — | -23,384,000 |
| Dec 2022 | 292,484,000 | -64,846,000 | -94,226,000 | 356,054,000 | 350,824,000 | — | -73,154,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$37,428,000
NetIncome TTM
$-20,039,000
OpCashFlow TTM
$0
Assets (Latest)
$220,670,000
Forward EPS
$-0.33
Max Pain — expiry 2027-01-15
max pain strike: $1.50 · spot: $0.90 · call oi: 3,424 · put oi: 1,885
Expected Move to 2027-01-15:
±$0.42
(47.19%) —
implied range
$0.48 –
$1.33
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd. | $251.15M | $77.39 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $251.62M | $14.30 | — |
| VRXA | Veraxa Biotech AG - Post de-SPAC | $251.71M | $1.78 | — |
| PYXS | Pyxis Oncology, Inc. | $246.89M | $2.96 | — |
| SION | Sionna Therapeutics, Inc. | $252.74M | $5.59 | — |
News headlines (Yahoo Finance, 1h cache)
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
2026-08-06 05:10 · Yahoo
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
2026-08-05 22:10 · Yahoo
Akebia Therapeutics Q2 Earnings Call Highlights
2026-08-05 22:03 · Yahoo
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-07-29 12:00 · Yahoo
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
2026-06-30 13:10 · Yahoo
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
2026-06-10 12:00 · Yahoo
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
2026-06-05 00:05 · Yahoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Akebia (AKBA) Q1 2026 Earnings Transcript
2026-05-08 15:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.